Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

141. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis (Full text)

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C CRD summary The authors concluded that there were differences (...) in fracture risk reduction profiles between pharmacologic therapies for postmenopausal osteoporosis and the findings may assist therapy choice. The authors’ conclusions are generally suitably cautious but it remains unclear which of the treatments for osteoporosis most effective. Authors' objectives To assess the effectiveness of postmenopausal osteoporosis therapies in reducing fracture risk. Searching MEDLINE (from 1950), EMBASE (from 1980), CINAHL and Cochrane Central Register of Controlled Trials

2014 DARE. PubMed

142. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis (Full text)

Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Ding H, Yang L, Du W, Teng Y, Fu SJ, Tao (...) of bisphosphonates for prevention and treatment of osteoporosis in men with non-metastatic prostate cancer receiving androgen deprivation therapy. Searching PubMed, EMBASE, The Cochrane Library, Science Citation Index, and Chinese Biomedicine Database were searched up to October 2012 with no language restrictions. Google was searched for related references. Reference lists of relevant studies were also searched and experts in the field contacted. Only published studies were sought. Study selection Randomised

2014 DARE. PubMed

143. Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients ? a systematic review and meta-analysis (Full text)

Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients ? a systematic review and meta-analysis Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients – a systematic review and meta-analysis Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury (...) osteoporosis in spinal cord injury patients – a systematic review and meta-analysis Chang KV, Hung CY, Chen WS, Lai MS, Chien KL, Han DS CRD summary The authors concluded that the early administration of bisphosphonates after spinal cord injury effectively reduced sub-lesional bone loss. Functional electrical stimulation for chronic injury could significantly increase sub-lesional bone mineral density. They relied on before-and-after data, which limits the comparison of intervention effectiveness. Small

2014 DARE. PubMed

144. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A. Denosumab versus bifosfonatos para el tratamiento de la osteoporosis

2014 Health Technology Assessment (HTA) Database.

145. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis

Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2014 DARE.

146. Osteoporosis in Menopause

Osteoporosis in Menopause Osteoporosis in Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Pages 839–840 Osteoporosis in Menopause PRINCIPAL AUTHORS, x Aliya Khan , MD Hamilton ON x Michel Fortier , MD Quebec QC x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x (...) text on ScienceDirect. Abstract Objective To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal osteoporosis. Outcomes Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage

2014 Society of Obstetricians and Gynaecologists of Canada

147. Sclerostin Inhibition for Osteoporosis - A New Approach. (PubMed)

Sclerostin Inhibition for Osteoporosis - A New Approach. 24382003 2014 02 11 2018 12 03 1533-4406 370 5 2014 Jan 30 The New England journal of medicine N. Engl. J. Med. Sclerostin inhibition for osteoporosis--a new approach. 476-7 10.1056/NEJMe1315500 Becker Carolyn B CB From Brigham and Women's Hospital, Boston. eng Editorial Comment 2014 01 01 United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Bone Density Conservation Agents 3VHF2ZD92J AMG 785 AIM IM N Engl J Med. 2014 (...) Jan 30;370(5):412-20 24382002 Antibodies, Monoclonal administration & dosage Bone Density drug effects Bone Density Conservation Agents administration & dosage Bone Remodeling drug effects Female Humans Osteoporosis, Postmenopausal drug therapy 2014 1 3 6 0 2014 1 3 6 0 2014 2 12 6 0 ppublish 24382003 10.1056/NEJMe1315500

2014 NEJM

148. [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]

[Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription (...) drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Tremblay E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2014 Health Technology Assessment (HTA) Database.

149. PLS3 mutations in X-linked osteoporosis with fractures. (Full text)

PLS3 mutations in X-linked osteoporosis with fractures. Plastin 3 (PLS3), a protein involved in the formation of filamentous actin (F-actin) bundles, appears to be important in human bone health, on the basis of pathogenic variants in PLS3 in five families with X-linked osteoporosis and osteoporotic fractures that we report here. The bone-regulatory properties of PLS3 were supported by in vivo analyses in zebrafish. Furthermore, in an additional five families (described in less detail) referred (...) for diagnosis or ruling out of osteogenesis imperfecta type I, a rare variant (rs140121121) in PLS3 was found. This variant was also associated with a risk of fracture among elderly heterozygous women that was two times as high as that among noncarriers, which indicates that genetic variation in PLS3 is a novel etiologic factor involved in common, multi-factorial osteoporosis.

2013 NEJM PubMed

150. Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia

Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia Osteoporosis imposes a tremendous burden on Australia: 1.2 million Australians have osteoporosis and 6.3 million have osteopenia. In the 2007–08 financial year, 82 000 Australians suffered fragility fractures, of which > 17 000 were hip fractures. In the 2000–01 financial year, direct costs were estimated at $1.9 billion per year and an additional $5.6 billion on indirect costs (...) . Osteoporosis was designated a National Health Priority Area in 2002; however, implementation of national plans has not yet matched the rhetoric in terms of urgency. Building healthy bones throughout life, the Osteoporosis Australia strategy to prevent osteoporosis throughout the life cycle, presents an evidence-informed set of recommendations for consumers, health care professionals and policymakers. The strategy was adopted by consensus at the Osteoporosis Australia Summit in Sydney, 20 October 2011

2013 Clinical Practice Guidelines Portal

151. Odanacatib for male osteoporosis ? first and second line

Odanacatib for male osteoporosis ? first and second line Odanacatib for male osteoporosis – first and second line Odanacatib for male osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Odanacatib for male osteoporosis – first and second line. Birmingham: NIHR Horizon Scanning Centre (...) (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biphenyl Compounds /therapeutic use; Humans; Male; Men; Osteoporosis /drug therapy Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham

2013 Health Technology Assessment (HTA) Database.

152. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) tool aiding in the diagnosis of osteoporosis? Clinical Bottom Line Evidence shows that Eroded Appearance of the Inferior Mandibular cortex in a panoramic radiograph is an Effective Indicator for osteoporosis in postmenopausal women. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Taguchi/2004 316 women with a mean age 56.8 were recruited for this study subjects were divided into Two Groups: 159 Healthy

2013 UTHSCSA Dental School CAT Library

153. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. (Full text)

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone.From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis into this randomised

2013 Lancet PubMed

154. Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines

Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines TITLE: Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines DATE: 05 June 2013 RESEARCH QUESTIONS 1. What is the clinical evidence regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis compared to standard BMD scanners? 2. What (...) are the evidence-based guidelines regarding the use of portable BMD scanners for screening and diagnosis of osteoporosis? KEY MESSAGE Three non-randomized studies were identified regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis compared to standard BMD scanners. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2013, Issue 4), University of York Centre for Reviews

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

155. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. (Full text)

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. This report identifies human skeletal diseases associated with mutations in WNT1. In 10 family members with dominantly inherited, early-onset osteoporosis, we identified a heterozygous missense mutation in WNT1, c.652T→G (p.Cys218Gly). In a separate family with 2 siblings affected by recessive osteogenesis imperfecta, we identified a homozygous nonsense mutation, c.884C→A, p.Ser295*. In vitro, aberrant forms of the WNT1

2013 NEJM PubMed

156. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. (Full text)

Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Osteoporosis is a prevalent but underdiagnosed condition.To evaluate computed tomography (CT)-derived bone mineral density (BMD) assessment compared with dual-energy x-ray absorptiometry (DXA) measures for identifying osteoporosis by using CT scans performed for other clinical indications.Cross-sectional study.Single academic health center.1867 adults undergoing CT and DXA (n (...) = 2067 pairs) within a 6-month period over 10 years.CT-attenuation values (in Hounsfield units [HU]) of trabecular bone between the T12 and L5 vertebral levels, with an emphasis on L1 measures (study test); DXA BMD measures (reference standard). Sagittal CT images assessed for moderate-to-severe vertebral fractures.CT-attenuation values were significantly lower at all vertebral levels for patients with DXA-defined osteoporosis (P < 0.001). An L1 CT-attenuation threshold of 160 HU or less was 90

2013 Annals of Internal Medicine PubMed

157. Osteoporosis - Diagnosis and Treatment

Osteoporosis - Diagnosis and Treatment Osteoporosis: Diagnosis, Treatment and Fracture Prevention - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend theme_5_collection (...) theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Recommendations and Topics Scope Osteoporosis (OP) is a significant risk factor for fragility

2013 Clinical Practice Guidelines and Protocols in British Columbia

158. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry

159. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry

160. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry